Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 2, 2011, Pages 155-159

  Blesa, Joan Manel Gasent ^a   Marco, Vicente Giner ^b   Giner Bosch, Vicente ^c   Fuentes, Pablo Cerezuela ^d   Candel, Vicente Alberola ^e  

^a Hospital de Denia   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL DE SAGUNTO   (Spain)

^d Hospital Virgen del Rosell   (Spain)

^e UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

Chemotherapy; Hormono refractory; Prostate cancer; Second line

Indexed keywords

ANDROGEN; CAPECITABINE; DOCETAXEL; OXALIPLATIN; PREDNISONE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 79955978262     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d6b453     Document Type: Article

References (22)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29. (Pubitemid 38443417)
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520. (Pubitemid 39315318)
4. Schilsky RL, Bertucci D, Vogelzang NJ, et al. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002;20:582-587. (Pubitemid 34072543)
5. Morant R, Bernhard J, Dietrich D, et al. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer. 2004;90:1312-1317. (Pubitemid 38586253)
6. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990;25:299-303. (Pubitemid 20014976)
7. Chen Y, Wang J, Fraig MM, et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 2001;61:4112-4121. (Pubitemid 32720979)
8. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs. 1997;8:876-885. (Pubitemid 27487802)
9. Kuzel T, Tallman M, Shevrin D, et al. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center study. Cancer. 1993;72:1965-1968. (Pubitemid 23262129)
10. Atkins J, Muss HB, Case D, et al. High-dose 24 hour infusion of 5-fluorouracil in metastatic prostate cancer: a phase II trial of the Piedmont Oncology Association. J Clin Oncol. 1996;14:526-529.
11. Huan S, Aitken S, Stewart DJ. 5-Fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study. Ann Oncol. 1994;5:644-645. (Pubitemid 24283103)
12. Droz JP, Muracciole X, Mottet N, et al. Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol. 2003;14:1291-1298. (Pubitemid 37039058)
13. Berthold DR, Pond GR, de Wit R, et al; On behalf of the TAX 327 investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol. 2008;19:1749-1753.
14. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Speciflc AntigenWorking Group. J Clin Oncol. 1999;17:3461-3467. (Pubitemid 29517916)
15. Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst. 1990;82:1046-1050. (Pubitemid 20204976)
16. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol. 2009;20:703-708.
17. Beer TM, Garzotto M, Henner WD, et al. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2004;91:1425-1427. (Pubitemid 39486342)
18. Beet TM, Ryan CW, Venner PM, et al. Intermitent chemotherapy in patients with metastatic androgen independent prostate cancer: results from ASCENT, a double blinded, randomized comparison of high dose calcitriol plus docetaxel with placebo with docetaxel. Cancer. 2003;112:326-330.
19. Eymard J, Oudard S, Gravis G, et al. Second-line chemotherapy with docetaxel (D) in men treated with docetaxel-based regimen for metastatic hormonerefractory prostate cancer (HRPC). In: ASCO Prostate Cancer Symposium. 2007. Abstract 249. February 22-24, 2007 in Orlando, Florida.
20. Rosenberg JE, Weinberg V, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556-563. (Pubitemid 47106144)
21. Ross RW, Beer TM, Jacobus S, et al. A phase II trial of carboplatin plus docetaxel in hormone-refractory prostate cancer patients who have refractory after docetaxel chemotherapy. Cancer. 2008;112:521-526. (Pubitemid 351186193)
22. Oh WK, Manola J, Babcic V, et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology. 2006;67:1235-1240. (Pubitemid 43818095)